Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Recurrent Ovarian Cancer with BRCAness Phenotype: A Treatment Challenge.

Advances in therapy - 1 Nov 2022

Caeiro Cláudia, Leão Inês, Oliveira Inês, Sousa Isabel, André Teresa

Abstract excerpt

INTRODUCTION: Ovarian cancer is a leading cause of death among women with gynecologic malignancies. The relapse rate is high after platinum-based therapy, with the effectiveness of subsequent treatment lines decreasing over time. Recent data suggest the benefit of maintenance therapy with niraparib in platinum-sensitive recurrent disease. CASE PRESENTATIONS: We report a case series of five women with advanced...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Ovarian Epithelial
Share to Neoplasm Recurrence, Local
Share to Ovarian Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Phenotype

Share to Poly(ADP-ribose) Polymerase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 36063278
DOI: 10.1007/s12325-022-02259-2
PMCID: PMC9442551

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Recurrent Ovarian Cancer with BRCAness Phenotype: A Treatment Challenge.PMID 36063278Read ↗

Recurrent Ovarian Cancer in BRCAness Phenotype: A Treatment ChallengeSemantic proximity Read ↗

Niraparib for the treatment of ovarian cancer.Semantic proximity Read ↗

PARP inhibitors: Clinical utility and possibilities of overcoming resistanceSemantic proximity Read ↗

Niraparib and Advanced Ovarian Cancer: A Beacon in the Non-BRCA Mutated SettingSemantic proximity Read ↗

Real-World Efficacy and Safety of PARP Inhibitors in Recurrent Ovarian Cancer Patients With Somatic BRCA and Other Homologous Recombination Gene Mutations.Semantic proximity Read ↗

PARPis after PARPis in patients with recurrent epithelial ovarian cancer: A single institutional experienceSemantic proximity Read ↗

Current Ovarian Cancer Maintenance Strategies and Promising New DevelopmentsSemantic proximity Read ↗

PARP Inhibitors in Ovarian Cancer: Resistance Mechanisms, Clinical Evidence, and Evolving StrategiesSemantic proximity Read ↗

BRCAness: Finding the Achilles Heel in Ovarian CancerSemantic proximity Read ↗

Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination SystemSemantic proximity Read ↗

Ovarian cancer recurrence: “is the definition of platinum resistance modified by PARP inhibitors and other intervening treatments?”Semantic proximity Read ↗

BRCA gene amplification in primary peritoneal high-grade serous carcinoma patient with intrinsic resistance to platinum treatment: a case report.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.